- Home
- AKYA vs IKNA Comparison
AKYA vs IKNA Comparison
Compare AKYA & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKYA
- IKNA
- Stock Information
- Founded
- AKYA 2015
- IKNA 2016
- Country
- AKYA United States
- IKNA United States
- Employees
- AKYA N/A
- IKNA N/A
- Industry
- AKYA Medical Specialities
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- AKYA Industrials
- IKNA Health Care
- Exchange
- AKYA Nasdaq
- IKNA Nasdaq
- Market Cap
- AKYA 56.1M
- IKNA 52.1M
- IPO Year
- AKYA 2021
- IKNA 2021
- Fundamental
- Price
- AKYA $1.24
- IKNA $1.18
- Analyst Decision
- AKYA Hold
- IKNA Buy
- Analyst Count
- AKYA 7
- IKNA 2
- Target Price
- AKYA $2.51
- IKNA $3.00
- AVG Volume (30 Days)
- AKYA 1.1M
- IKNA 109.0K
- Earning Date
- AKYA 05-12-2025
- IKNA 05-08-2025
- Dividend Yield
- AKYA N/A
- IKNA N/A
- EPS Growth
- AKYA N/A
- IKNA N/A
- EPS
- AKYA N/A
- IKNA N/A
- Revenue
- AKYA $79,961,000.00
- IKNA N/A
- Revenue This Year
- AKYA $12.57
- IKNA N/A
- Revenue Next Year
- AKYA $13.73
- IKNA N/A
- P/E Ratio
- AKYA N/A
- IKNA N/A
- Revenue Growth
- AKYA N/A
- IKNA N/A
- 52 Week Low
- AKYA $0.93
- IKNA $0.97
- 52 Week High
- AKYA $3.42
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- AKYA 52.88
- IKNA 53.94
- Support Level
- AKYA $1.21
- IKNA $1.10
- Resistance Level
- AKYA $1.26
- IKNA $1.20
- Average True Range (ATR)
- AKYA 0.08
- IKNA 0.08
- MACD
- AKYA 0.02
- IKNA 0.01
- Stochastic Oscillator
- AKYA 60.71
- IKNA 74.70
About AKYA Akoya BioSciences Inc.
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.